Quality of life and symptoms in male breast cancer survivors

Quality of life and symptoms in male breast cancer survivors. The breast, Vol. 22(2), April 2013, p.197-9.

Ruddy, K.J., et al.

http://www.thebreastonline.com/article/PIIS0960977612002585/abstract?rss=yes

Little is known about quality of life and symptoms of male breast cancer survivors.

A new level 1 oncoplastic technique for breast conserving surgery

A new level 1 oncoplastic technique for breast conserving surgery: Rotation gladular flap. The breast, Vol. 22(2), April 2013, p.186-9.

Massey, E.J.D., et al.

http://www.thebreastonline.com/article/PIIS0960977613000143/abstract?rss=yes

When performing conservative surgery for breast cancer, breast reshaping can be a challenging procedure. Level 1 oncoplastic surgery (OPS) techniques, i.e. advancement or rotation of glandular flaps, should be performed when less than 20 per cent breast volume is excised.

Trends in tertiary breast reconstruction

Trends in tertiary breast reconstruction: Literature review and single centre experience. The breast, Vol. 22(2), April 2013, p.173-8.

Mohan, A.T., et al.

http://www.thebreastonline.com/article/PIIS0960977612001166/abstract?rss=yes

Autologous flap reconstruction can improve aesthetic results after failed implant reconstruction and be considered following previous failed autologous flap reconstruction. This study presents a review of the indications, motivation and outcomes of tertiary breast reconstruction.

An evaluation of patient reported outcomes following breast reconstruction utilizing Breast Q.

An evaluation of patient reported outcomes following breast reconstruction utilizing Breast Q.  The breast, Vol. 22(2), April, 2013, p.158-161.

Sugrue, R., et al.

http://www.thebreastonline.com/article/PIIS0960977612002457/abstract?rss=yes

Breast Q questionnaire measures patient's perceptions following breast reconstruction using quality of life and satisfaction. This study assessed patient reported outcomes following mastectomy and reconstruction utilizing Breast Q.

Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer

Aromatase inhibitors in the treatment of elderly women with metastatic breast cancer. The breast, Vol. 22(2), April 2013, p.142-9.

Gluck, S., et al.

http://www.thebreastonline.com/article/PIIS0960977612002597/abstract?rss=yes

The proportion of elderly women in the population is rising, and in tandem, the incidence of breast cancer rises with age. Because of health and tolerability concerns, as well as life expectancy, physicians may be reluctant to advise a standard treatment regimen for elderly patients with metastatic breast cancer. 

Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are not suitable for a "standard chemotherapy regimen"

Adjuvant pegylated liposomal doxorubicin for older women with endocrine nonresponsive breast cancer who are not suitable for a "standard chemotherapy regimen": The CASA randomized trial.  The breast, Vol. 22(2), April 2013, p.130-7.

Crivellari, D., et al.

http://www.thebreastonline.com/article/PIIS0960977613000179/abstract?rss=yes

There is no optimal treatment for breast cancers lacking estrogen (ER) and progesterone (PgR) receptors in elderly women with co-morbidities that prevent use of “standard chemotherapy regimens” such as AC or CMF. The CASA trial studied pegylated liposomal doxorubicin and low dose, metronomic cyclophosphamide + methotrexate (CM) for older (>65), vulnerable women with operable, ER and PgR-negative breast cancer.

Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women

Meta-analysis of breast cancer outcome and toxicity in adjuvant trials of aromatase inhibitors in postmenopausal women. The breast, Vol. 22(2), April 2013, p.121-29.

Aydiner, A.

http://www.thebreastonline.com/article/PIIS0960977613000167/abstract?rss=yes

The present meta-analysis examines randomized trials of third-generation aromatase inhibitors (AIs) as alternatives to tamoxifen in three treatment settings: monotherapy, sequenced therapy and extended therapy. Eleven randomized controlled trials (RCTs) were chosen based on their similarity in terms of study design and included 34,070 post-menopausal women who had undergone surgery for estrogen-sensitive early breast cancer.

Gene expression profiling in breast cancer

Gene expression profiling in breast cancer: A clinical perspective. The breast, Vol. 22(2), April 2013, p.109-120.

Arpino, G., et al.

http://www.thebreastonline.com/article/PIIS0960977613000180/abstract?rss=yes

Gene expression profiling tests are used in an attempt to determine the right treatment for the right person with early-stage breast cancer that may have spread to nearby lymph nodes but not to distant parts of the body. These new diagnostic approaches are designed to spare people who do not need additional treatment (adjuvant therapy) the side effects of unnecessary treatment, and allow people who may benefit from adjuvant therapy to receive it.

Overview of the evidence on digital breast tomosynthesis in breast cancer detection

Overview of the evidence on digital breast tomosynthesis in breast cancer detection. The breast, Vol. 22(2), April 2013, p.101-08.

Houssami, N. and Skaane, P.

http://www.thebreastonline.com/article/S0960-9776(13)00019-2/abstract

Digital breast tomosynthesis (DBT, or 3D-mammography), a three-dimensional derivative of digital mammography, reduces the effect of tissue superimposition and may improve mammographic interpretation. In this review, we examined the evidence on the accuracy of DBT in clinical studies. Published studies of DBT were relatively small studies, mostly test-set observer (reader) studies or clinical series that included symptomatic and screen-recalled cases, and were generally enriched with cancers.